Advertisement

Topics

Roche lines up February decision date for hemophilia prospect

05:10 EDT 24 Aug 2017 | BioPharmaDive

If approved, emicizumab could threaten both Shire and Novo Nordisk's respective hemophilia businesses.

Original Article: Roche lines up February decision date for hemophilia prospect

NEXT ARTICLE

More From BioPortfolio on "Roche lines up February decision date for hemophilia prospect"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...